8-K: Centene Reaffirms 2024 EPS Guidance and Expects Continued Growth

Centene Corporation's senior management team reaffirmed their 2024 full-year adjusted diluted earnings per share guidance of greater than $6.80 and expects to grow adjusted diluted EPS in 2025 and beyond.

Summary

• Centene Corporation's management team met with investors on November 13, 2024.
• They reaffirmed the company's 2024 full-year adjusted diluted earnings per share (EPS) guidance of greater than $6.80.
• The company also expects to grow adjusted diluted EPS in 2025 and beyond.
• Centene uses non-GAAP financial measures to assess performance, focusing on core business operations.
• The company acknowledges the difficulty in reconciling its 2024 adjusted diluted EPS guidance to GAAP measures due to unpredictable items.
• The document includes forward-looking statements subject to risks and uncertainties.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the reaffirmation of guidance and the expectation of future growth, but tempered by the numerous risks and uncertainties outlined in the document.

Positives

• The reaffirmation of the 2024 EPS guidance provides stability and confidence to investors.
• The expectation of continued EPS growth in 2025 and beyond signals a positive outlook for the company's future performance.
• The use of non-GAAP measures allows investors to better understand the company's core operational performance.

Negatives

• The company is unable to provide a reconciliation of its 2024 adjusted diluted EPS guidance to the most directly comparable GAAP financial measure without unreasonable effort.
• The forward-looking statements are subject to various risks and uncertainties, which could impact actual results.

Risks

• The company's performance is subject to economic, regulatory, and competitive factors.
• There are risks related to healthcare practices, new technologies, and advances in medicine.
• The company faces risks related to government healthcare programs and changes in laws and regulations.
• Cyber-attacks and data security incidents pose a risk to the company.
• The company's ability to maintain or improve CMS Star ratings can impact revenue and future growth.
• The company's ability to accurately predict and manage health benefits and other operating expenses is a risk.
• The company faces risks related to competition, including for providers, broker distribution networks, contract reprocurements and organic growth.
• The company's ability to manage its information systems effectively is a risk.
• Disruptions, unexpected costs, or similar risks from business transactions, including acquisitions, divestitures, and changes in relationships with third parties are a risk.
• Impairments to real estate, investments, goodwill and intangible assets are a risk.
• Changes in senior management, loss of key personnel or an inability to attract, hire, integrate and retain skilled personnel are a risk.
• Membership and revenue declines or unexpected trends are a risk.
• Rate cuts or other payment reductions or delays by governmental payors and other risks and uncertainties affecting government businesses are a risk.
• The company faces risks related to the effect of social, economic, and political conditions and geopolitical events.
• The company faces risks related to changes in market conditions.
• The company faces risks related to uncertainty concerning government shutdowns, debt ceilings or funding.
• The company faces risks related to tax matters.
• The company faces risks related to disasters, climate-related incidents, acts of war or aggression or major epidemics.
• The company faces risks related to changes in expected contract start dates and terms.
• The company faces risks related to changes in provider, broker, vendor, state, federal and other contracts and delays in the timing of regulatory approval of contracts.
• The company faces risks related to the expiration, suspension, or termination of contracts with federal or state governments.
• The company faces risks related to the difficulty of predicting the timing or outcome of legal or regulatory audits, investigations, proceedings or matters.
• The company faces risks related to challenges to contract awards.
• The company faces risks related to the exertion of management's time and resources, and other expenses incurred and business changes required in connection with complying with the terms of contracts.
• The company faces risks related to any changes in expected closing dates, estimated purchase price, or accretion for acquisitions or dispositions.
• The company faces risks related to losses in the investment portfolio.
• The company faces risks related to restrictions and limitations in connection with indebtedness.
• The company faces risks related to a downgrade of the corporate family rating, issuer rating or credit rating of indebtedness.
• The company faces risks related to the availability of debt and equity financing on terms that are favorable to the company.

Future Outlook

The company expects to grow adjusted diluted EPS in 2025 and beyond.

Management Comments

• The senior management team plans to reaffirm the Company's 2024 full year adjusted diluted earnings per share (EPS) guidance of greater than $6.80.
• The senior management team also plans to reiterate that the Company expects to grow adjusted diluted EPS in 2025 and beyond.

Industry Context

This announcement is consistent with the ongoing focus on financial performance and growth in the managed healthcare industry. Reaffirming guidance is a common practice to maintain investor confidence.

Comparison to Industry Standards

• Reaffirming EPS guidance is a common practice among publicly traded healthcare companies, such as UnitedHealth Group (UNH) and Humana (HUM), to provide investors with clarity on expected financial performance.
• The focus on non-GAAP measures is also a standard practice in the industry, allowing for a clearer view of core operational performance, similar to how companies like CVS Health (CVS) present their financials.
• The expectation of continued EPS growth is a key metric that investors use to compare companies within the managed care sector, and Centene's outlook is in line with the growth expectations of its peers.

Stakeholder Impact

• Shareholders will likely view the reaffirmation of guidance and growth expectations positively.
• Employees may feel more secure with the company's positive outlook.
• Customers may not be directly impacted by this announcement, but the company's financial health is important for service delivery.
• Suppliers and creditors may have increased confidence in the company's ability to meet its obligations.

Key Dates

Keywords

EPS, Earnings Per Share, Guidance, Healthcare, Non-GAAP, Financial Performance, Centene, Managed Care, Medicaid, Medicare